We surmise that oncogenic addiction to proliferation of T-ALL blasts conveys a vulnerability to dCK inhibitors and positions OR0642 as a promising candidate to treat acute leukemias. The gene discussed is DCK; the disease is acute lymphoblastic leukemia.